|
|
Substance Name: Lapatinib [INN:BAN]
RN: 231277-92-2
UNII: 0VUA21238F
InChIKey: BCFGMOOMADDAQU-UHFFFAOYSA-N
Note
- A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (RECEPTOR, ERBB-2) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.
Molecular Formula
- C29-H26-Cl-F-N4-O4-S
Molecular Weight
- 581.065
Classification Codes
- Antineoplastic
- Antineoplastic Agents
- Antiviral (COVID-19)
- Dual EGFR/erbB2 Inhibitors
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Lapatinib [INN:BAN]
MeSH Heading
- Lapatinib
Synonyms
- GSK 572016
- GW 572016
- GW572016
- HSDB 8209
- Lapatinib
- Tykerb
- UNII-0VUA21238F
Systematic Name
- 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-
Registry Numbers
CAS Registry Number
- 231277-92-2
FDA UNII
- 0VUA21238F
System Generated Number
- 0231277922